Fulcrum therapeutics® reports inducement grants under nasdaq listing rule 5635(c)(4)

Cambridge, mass., june 10, 2022 (globe newswire) -- fulcrum therapeutics, inc. (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the company granted nonstatutory stock options to new employees as inducement awards outside of the company's 2019 stock incentive plan. fulcrum granted stock options to purchase an aggregate of 112,800 shares of the company's common stock to eight new employees. the awards were granted as of june 6, 2022, pursuant to the company's 2022 inducement stock incentive plan, each as an inducement material to the new employees entering into employment with the fulcrum therapeutics in accordance with nasdaq listing rule 5635(c)(4).
FULC Ratings Summary
FULC Quant Ranking